Abstract

Renal outer medullary K+ channel, ROMK (Kir1.1, kcnj1) is expressed in the kidney and brain, but its role in the central nervous system remains unknown. Recent studies suggested an involvement of the ROMK channel in mental diseases. Tertiapin (TPN) is a European honey bee venom peptide and is reported to selectively block the ROMK channel. Here, we have chemically synthesized a series of mutated TPN peptides, including TPN-I8R and -M13Q (TPN-RQ), reported previously, and examined their blocking activity on the ROMK channel. Among 71 peptides tested, TPN-RQ was found to block the ROMK channel most effectively. Whole-cell patch-clamp recordings showed the essential roles of two disulfide bonds and the circular structure for the blockade activity. To examine the central role, we injected TPN-RQ intracerebroventricularly and examined the effects on depression- and anxiety-like behaviors in mice. TPN-RQ showed an antidepressive effect in tail-suspension and forced swim tests. The injection of TPN-RQ also enhanced the anxiety-like behavior in the elevated plus-maze and light/dark box tests and impaired spontaneous motor activities in balance beam and wheel running tests. Administration of TPM-RQ suppressed the anti-c-Fos immunoreactivity in the lateral septum, without affecting immunoreactivity in antidepressant-related nuclei, e.g. the dorsal raphe nucleus and locus coeruleus. TPN-RQ may exert its antidepressive effects through a different mechanism from current drugs.

Highlights

  • Major depression is a mood disorder with high prevalence and is mostly treated with antidepressants, such as selective serotonin reuptake inhibitors (SSRI) and serotonin-norepinephrine reuptake inhibitors (SNRI)

  • We show the antidepressive effects of a renal outer medullary K+ (ROMK) blocker, TPN-I8R and -M13Q (TPN-RQ), suggesting the involvement of this channel in depression

  • The decreases in the number of total line crossings in the open-field test (OFT), entry to open arm in the elevated plus maze (EPM), and transitions in the light/dark box test (LDT) can be explained with both anxiogenic effects and motor impairment

Read more

Summary

Introduction

Major depression is a mood disorder with high prevalence and is mostly treated with antidepressants, such as selective serotonin reuptake inhibitors (SSRI) and serotonin-norepinephrine reuptake inhibitors (SNRI). According to the STAR D study, conducted by the American National Institute of Mental Health, current drugs are ineffective in 30% of patients with major depression [1]. It is noteworthy that neurostimulation therapies, i.e., electric convulsive therapy, deep brain stimulation, and transcranial magnetic stimulation, are effective in some drug-resistant depression [2, 3]. It is assumed that the neuronal activities of some nuclei are dysregulated in patients: these neurostimulation therapies compensate for the dysregulated neuronal activity. If they do so, we expect that the pharmacological modulation

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call